Jim Simons’s OptimizeRx OPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.36M Buy
216,856
+187,278
+633% +$1.74M ﹤0.01% 2110
2025
Q4
$363K Sell
29,578
-78,322
-73% -$1.28M ﹤0.01% 2704
2025
Q3
$2.21M Buy
107,900
+30,193
+39% +$479K ﹤0.01% 2002
2025
Q2
$1.05M Buy
+77,707
New +$850K ﹤0.01% 2494
2024
Q4
Sell
-67,500
Closed -$521K 3810
2024
Q3
$521K Sell
67,500
-74,646
-53% -$663K ﹤0.01% 2775
2024
Q2
$1.42M Buy
142,146
+71,700
+102% +$788K ﹤0.01% 2106
2024
Q1
$856K Sell
70,446
-21,899
-24% -$318K ﹤0.01% 2578
2023
Q4
$1.32M Buy
+92,345
New +$886K ﹤0.01% 2219
2023
Q3
Sell
-63,500
Closed -$907K 3973
2023
Q2
$907K Sell
63,500
-120,900
-66% -$1.72M ﹤0.01% 2528
2023
Q1
$2.7M Buy
184,400
+143,417
+350% +$2.4M ﹤0.01% 1838
2022
Q4
$689K Buy
40,983
+8,783
+27% +$152K ﹤0.01% 2750
2022
Q3
$477K Sell
32,200
-13,824
-30% -$273K ﹤0.01% 2948
2022
Q2
$1.26M Sell
46,024
-43,976
-49% -$1.3M ﹤0.01% 2552
2022
Q1
$3.39M Buy
90,000
+81,300
+934% +$3.6M ﹤0.01% 1842
2021
Q4
$540K Buy
+8,700
New +$659K ﹤0.01% 3039
2019
Q3
Sell
-32,100
Closed -$520K 3628
2019
Q2
$520K Buy
+32,100
New +$433K ﹤0.01% 2979

Other funds holding OPRX

Jim Simons's OPRX Position: Q1 2026 in Review

Jim Simons increased its OptimizeRx (OPRX) stake by 633% in Q1 2026, buying an estimated $1.74M and bringing the position to 216,856 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2110.

Jim Simons first reported a position in OPRX in Q2 2019 and has held it in 16 quarters since. The position peaked at $3.39M in Q1 2022. 127 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.

  • Jim Simons held 216,856 shares of OptimizeRx worth $1.36M as of Q1 2026.
  • Jim Simons bought 187,278 OptimizeRx shares in Q1 2026, an estimated $1.74M.
  • OptimizeRx made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2110 holding.
  • Jim Simons first reported a position in OptimizeRx in Q2 2019 and has held it in 16 quarters since.
  • Jim Simons's OptimizeRx position peaked at $3.39M in Q1 2022.
  • 127 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.